National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

MEK inhibitor GSK1120212
An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. MEK inhibitor GSK1120212 specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:GSK1120212



Previous:Medrol, medroxyprogesterone, Megace, megestrol acetate, MEK inhibitor AZD8330
Next:MEK inhibitor RDEA119, MEK inhibitor XL518, Melan-A VLP vaccine, melanoma helper peptide vaccine, meloxicam

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov